Heidi Overton faces Senate hearing as FDA seeks revival amid staffing cuts

Heidi Overton has been put forward to become the next FDA commissioner and will be questioned by the Senate health committee on Thursday. Her appointment arrives as the pace of biomedical innovation—ranging from personalized gene therapies to AI-driven efficiencies—outstrips the agency’s current staffing, which fell by about 3,500 employees after the April 2025 layoffs. Meanwhile, China is launching more Phase 1 trials than the United States, highlighting a shift in global drug development that the FDA must address.

Overton’s background includes shaping the initial Covid-19 response and maintaining close relationships with White House leaders, positioning her to navigate inter-agency reforms. The article cites recent actions by acting commissioner Kyle Diamantas to solidify career leadership in the drug, biologics, and tobacco centers, a move that could provide the continuity Overton needs to restore morale and advance priorities such as rare-disease treatments, vaccine policy, and tobacco regulation.